«The projects carried out by researchers at the Institut Bordet are exceptional in their cross-disciplinary nature and inventiveness. Driving healthcare forward and exploring all possible research avenues – this is the approach we take at the Institut Bordet. »
The term clinical research encompasses the studies and clinical trials that we carry out at the Institut Jules Bordet with our partners, academic research centres and pharmaceutical companies. The aims of these studies include:
- testing new diagnostic techniques;
- comparing a number of different therapeutic strategies;
- testing new and innovative medicines, particularly for cancers where no effective treatment currently exists.
Clinical research is only possible with patient involvement. Patient participation in clinical trials enables researchers to answer important research questions.
The principal roles of translational research are to understand cancer and identify markers that will assist in diagnosis, in predicting response to certain treatments and in patient prognosis. This type of research is based on the analysis of the blood and/or tumour samples that are removed, with the patient’s consent, during diagnosis or treatment. As an integral part of clinical research, the aim of translational research is to transform these findings rapidly into concrete options in the care offered to patients.
Conducting and organising clinical research
The Institut Jules Bordet participates in cancer research by running clinical trials designed by its researchers and by other research groups across the world. A number of bodies are involved in the organisation and running of clinical trials:
- The Ethics Committee: this is an independent committee that analyses and evaluates research projects before they are offered to patients.
- The Clinical Trials Support Unit (CTSU): this unit supports researchers by arranging different aspects of clinical trials (regulations, quality procedures, etc) with research partners.
- The Clinical Trials Conduct Unit (CTCU): this unit is composed of research nurses and investigative doctors who monitor the patients involved in clinical trials. The unit works in close collaboration with the medical oncology, haematology, imaging and psycho-oncology departments and others.
- The Administrative Research Management Unit (UGAR) is a centralised, administrative management unit for the research departments.
Collaboration for innovation
Research is always a collaborative activity, particularly so in the field of cancer. In order to explore the most promising avenues, the Institut Jules Bordet works together with other academic and/or private bodies.
Academic research is in the very DNA of the Institut Jules Bordet. Indeed, some prestigious research networks began their life here, including the EORTC, the BIG and, more recently the Oncodistinct network. Offering the best care for each patient is a complicated matter, given the complexity and diversity of their situations and the range of possible therapeutic strategies available. Therefore, medical staff need to question their practice rigorously, in particular by means of clinical trials. These trials take place in a university framework. Their results often have a significant and positive impact on the care offered to patients.
To find new drugs and new medical equipment for its patients, the Institut Jules Bordet supports and collaborates with those developing innovative treatments: pharmaceutical companies. Some clinical trials at the Institut Bordet are therefore carried out in partnership with these companies and always with the patient’s best interests in mind.
As a patient, you may be invited to take part in a clinical trial of a new treatment, a new medical investigation technique or an innovative approach to care. In addition to the benefits this may bring you personally, taking part in a clinical trial contributes to the advancement of medicine and helps future patients.
However, your participation in these studies is strictly voluntary, not obligatory. No research procedures will ever be carried out without your agreement. To help you decide with full knowledge of the facts and give what is called “informed patient consent”, you will receive comprehensive information verbally and in writing. Your referring physician will explain to you as fully and clearly as possible the potential risks and benefits of taking part in the clinical trial you have been offered.
Your health and your quality of life are our primary concern. If your health requires it, or if you so choose, you may end your participation in the clinical trial at any time.
Find a clinical trial
Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results.
Authors : Catala G, Mebis J, Jerusalem G, Verhoeven D, Awada A, Bols A, Somers L, Van Den Broeck A, Duhoux FP, Machiels JP
Year : 2019
Journal : Acta Clin Belg
Pages : 1-8
ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma.
Authors : Rashid M, van der Horst M, Mentzel T, Butera F, Ferreira I, Pance A, Rütten A, Luzar B, Marusic Z, de Saint Aubain N, Ko JS, Billings SD, Chen S, Abi Daoud M, Hewinson J, Louzada S, Harms PW, Cerretelli G, Robles-Espinoza CD, Patel RM, van der Weyden L, Bakal C, Hornick JL, Arends MJ, Brenn T, Adams DJ
Year : 2019
Journal : Nat Commun
Volume : 10
Pages : 2213
Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Authors : Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E, Lambertini M
Year : 2019
Journal : Breast Cancer Res Treat
Volume : 174
Pages : 27-37
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
Authors : Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D, Perez E, Piccart-Gebhart M, Schneider BP, Slamon D, Wolmark N, Buyse M
Year : 2019
Journal : Lancet Oncol
CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.
Authors : Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, Hendlisz A
Year : 2019
Journal : BMC Cancer
Volume : 19
Pages : 304